Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with variable clinical courses.
• Renal involvement is common and impacts patient outcomes.
• Conventional immunosuppressive therapies, while effective, are associated with flares and significant side effects.

Purpose of the Study:

• To review the application of biologic agents in SLE management.
• To highlight the role of targeted therapies in addressing unmet needs in SLE treatment.
• To evaluate the potential of biologics for improving patient outcomes and quality of life.

Main Methods:

• Review of current literature on biologic agents used in SLE.
• Analysis of targeted therapies including B cell and interferon pathway inhibitors.
• Discussion of approved and investigational biologic agents in SLE treatment.

Main Results:

• Biologic agents targeting specific pathogenic mechanisms have been successfully applied in SLE.
• Belimumab (B cell targeting), Rituximab (anti-CD20), and Anifrolumab (interferon I receptor targeting) show efficacy.
• These agents offer alternatives to broad immunosuppression, potentially reducing side effects.

Conclusions:

• Biologic treatments are increasingly utilized in SLE management.
• Further evaluation is needed to optimize treatment response and enhance patient quality of life.
• Targeted biologic therapies represent a significant advancement in managing SLE.